Pilaralisib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NamePilaralisib
Drug Alias Name匹拉利塞pilaralisibum匹雷利司SAR-245408XL-147
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitors
TargetsPI3-kinase class I
Therapy Area/IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungBreast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSpain +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiExelixis Inc
Active IndicationsN/A
Inactive IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungBreast Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A